Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage precision oncology company that completed its public debut in 2021 through a merger with BCTG Acquisition Corp, a blank-check vehicle sponsored by Baker Bros. Advisors LP. The company develops therapies targeting cancer vulnerabilities using its proprietary synthetic lethality discovery platform. Tango filed an 8-K with the SEC on August 11, 2026, continuing its disclosure obligations as a publicly listed company operating in the biopharmaceutical sector. The transaction remains one of the more prominent healthcare-focused SPAC deals from the 2021 cohort. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time data on TNGX and hundreds of other SPAC-linked companies.